Apellis Pharmaceuticals (APLS) Competitors $23.82 -0.57 (-2.34%) Closing price 04:00 PM EasternExtended Trading$23.82 0.00 (0.00%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. ASND, VTRS, RDY, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, and RVMDShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Do institutionals and insiders have more ownership in ASND or APLS? 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ASND or APLS? Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 23.89%. Apellis Pharmaceuticals has a consensus price target of $34.12, suggesting a potential upside of 43.23%. Given Apellis Pharmaceuticals' higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58 Is ASND or APLS more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Apellis Pharmaceuticals -30.24%-116.09%-26.72% Which has more risk & volatility, ASND or APLS? Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Does the media refer more to ASND or APLS? In the previous week, Apellis Pharmaceuticals had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 11 mentions for Apellis Pharmaceuticals and 8 mentions for Ascendis Pharma A/S. Apellis Pharmaceuticals' average media sentiment score of 1.35 beat Ascendis Pharma A/S's score of 1.24 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apellis Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ASND or APLS? Apellis Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M30.68-$409.12M-$5.16-38.22Apellis Pharmaceuticals$781.37M3.85-$197.88M-$1.82-13.09 SummaryApellis Pharmaceuticals beats Ascendis Pharma A/S on 11 of the 17 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-13.0921.1675.8626.51Price / Sales3.85446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book12.959.6212.796.29Net Income-$197.88M-$53.28M$3.28B$270.51M7 Day Performance-11.25%0.31%0.22%2.15%1 Month Performance-14.16%4.58%4.61%6.35%1 Year Performance-34.40%9.24%68.33%25.48% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.287 of 5 stars$23.82-2.3%$34.12+43.2%-35.2%$3.08B$781.37M-13.09770Positive NewsASNDAscendis Pharma A/S2.9554 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.6033 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.4264 of 5 stars$14.27-0.5%$16.95+18.8%-9.0%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.4124 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4139 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.20B$221.90M-13.27400Positive NewsAnalyst ForecastMRNAModerna4.5233 of 5 stars$24.83-1.2%$42.88+72.7%-65.0%$9.78B$3.24B-3.305,800News CoverageVRNAVerona Pharma PLC American Depositary Share2.2925 of 5 stars$106.300.0%$109.00+2.5%+257.2%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.8141 of 5 stars$19.02+3.2%$17.33-8.9%+28.7%$9.16B$4.44B22.129,000ROIVRoivant Sciences2.9525 of 5 stars$12.91-0.1%$16.38+26.8%+16.8%$8.82B$29.05M-18.44860RVMDRevolution Medicines4.2667 of 5 stars$41.06+1.4%$72.00+75.4%+5.7%$7.57B$11.58M-9.12250Insider TradeAnalyst Revision Related Companies and Tools Related Companies ASND Alternatives VTRS Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives VRNA Alternatives ELAN Alternatives ROIV Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts